Erratum: Autoimmune-induced damage of the midbrain dopaminergic system in lupus-prone mice (Journal of Neuroimmunology (2004) 152 (83-97) PII: S0165572804001201 and DOI: 10.1016/j.jneuroim.2004.04.003);Autoimmune-induced damage of the midbrain dopaminergic system in lupus-prone mice

Journal of Neuroimmunology

Volumn 152, Issue 1-2, 2004, Pages 83-97

  Ballok, David A ^a   Earls, Aoife M ^a   Krasnik, Catherine ^a   Hoffman, Steven A ^b   Sakic, Boris ^a,c  

^a MCMASTER UNIVERSITY   (Canada)

^b ARIZONA STATE UNIVERSITY   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Autoimmunity; Behavior; Brain reactive autoantibodies; Cerebrospinal fluid; Cyclophosphamide; Dopamine; Fluoro Jade B; Inflammation; Lupus; MRL mice; Neural progenitor cells; Substantia nigra; TNF ; Tyrosine hydroxylase; Ventral tegmental area

Indexed keywords

APOMORPHINE; CYCLOPHOSPHAMIDE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; BRAIN ATROPHY; BRAIN INJURY; BRAIN SIZE; CATABOLISM; CEREBROSPINAL FLUID; CIRCLING BEHAVIOR; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; GROOMING; IMMUNOSUPPRESSIVE TREATMENT; MESENCEPHALON; MOTOR DYSFUNCTION; MOUSE; NERVE DEGENERATION; NERVE ENDING; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; REARING; SOMATIC CELL; STAINING; STATISTICAL SIGNIFICANCE; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; SYSTEMIC LUPUS ERYTHEMATOSUS; VENTRAL TEGMENTUM;

EID: 3042513743     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2004.08.001     Document Type: Erratum

References (136)

1. Alexander E.L., Murphy E.D., Roths J.B., Alexander G.E. Congenic autoimmune murine models of central nervous system disease in connective tissue disorders. Ann. Neurol. 14:1983;242-248
2. Andrews B.S., Eisenberg R.A., Theofilopoulos A.N., Izui S., Wilson C.B., McConahey P.J., Murphy E.D., Roths J.B., Dixon F.J. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med. 148:1978;1198-1215
3. Arai N., Misugi K., Goshima Y., Misu Y. Evaluation of a 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. Brain Res. 515:1990;57-63
4. Asanuma M., Miyazaki I., Ogawa N. Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox. Res. 5:2003;165-176
5. Ballok D.A., Millward J.M., Sakic B. Neurodegeneration in autoimmune MRL-lpr mice as revealed by Fluoro Jade B staining. Brain Res. 964:2003;200-210
6. Ballok D.A., Szechtman H., Sakic B. Taste responsiveness and diet preference in autoimmune MRL mice. Behav. Brain Res. 140:2003;119-130
7. Ballok D.A., Woulfe J., Sur M., Cyr M., Sakic B. Hippocampal damage in mouse and human forms of systemic autoimmune disease. Hippocampus. 2004;. (DOI 10205)
8. Barone F.C., Arvin B., White R.F., Miller A., Webb C.L., Willette R.N., Lysko P.G., Feuerstein G.Z. Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke. 28:1997;1233-1244
9. Bello N.T., Sweigart K.L., Lakoski J.M., Norgen R., Hajnal A. Restricted feeding with scheduled sucrose access results in an upregulation of the rat dopamine transporter. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284:2003;R1260-1268
10. Beran M., O'Brien S., Andersson B., McCredie K.B., Gutterman J.U. Tumor necrosis factor and human hematopoiesis: II. Inhibition and mode of action on normal and chronic myelogenous leukemia-derived granulocyte-macrophage progenitor cells. Hematol. Pathol. 2:1988;65-71
11. Bluestein H.G., Zvaifler N.J. Brain-reactive lymphocytotoxic antibodies in the serum of patients with systemic lupus erythematosus. J. Clin. Invest. 57:1976;509-516
12. Bluestein H.G., Williams G.W., Steinberg A.D. Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus. Am. J. Med. 70:1981;240-246
13. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65:2001;135-172
14. Bosboom J.L., Stoffers D., Wolters E.C. The role of acetylcholine and dopamine in dementia and psychosis in Parkinson's disease. J. Neural Transm., Suppl. 2003;185-195
15. Bresnihan B., Hohmeister R., Cutting J., Travers R.L., Waldburger M., Black C., Jones T., Hughes G.R. The neuropsychiatric disorder in systemic lupus erythematosus: evidence for both vascular and immune mechanisms. Ann. Rheum. Dis. 38:1979;301-306
16. Brey R.L., Cote S., Barohn R., Jackson C., Crawley R., Teale J.M. Model for the neuromuscular complications of systemic lupus erythematosus. Lupus. 4:1995;209-212
17. Brey R.L., Amato A.A., Kagan-Hallet K., Rhine C.B., Stallworth C.L. Anti-intercellular adhesion molecule-1 (ICAM-1) antibody treatment prevents central and peripheral nervous system disease in autoimmune-prone mice. Lupus. 6:1997;645-651
18. Brooks W.M., Sabet A., Sibbitt W.L. Jr., Barker P.B., van Zijl P.C., Duyn J.H., Moonen C.T. Neurochemistry of brain lesions determined by spectroscopic imaging in systemic lupus erythematosus. J. Rheumatol. 24:1997;2323-2329
19. Cai G., Wang H.Y., Friedman E. Increased dopamine receptor signaling and dopamine receptor-G protein coupling in denervated striatum. J. Pharmacol. Exp. Ther. 302:2002;1105-1112
20. Cantello R., Aguggia M., Gilli M., Delsedime M., Chiardo C.I., Riccio A., Mutani R. Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse. J. Neurol. Neurosurg. Psychiatry. 52:1989;724-731
21. Clarke D.J., Branton R.L. A role for tumor necrosis factor alpha in death of dopaminergic neurons following neural transplantation. Exp. Neurol. 176:2002;154-162
22. Cohen G. Oxy-radical toxicity in catecholamine neurons. Neurotoxicology. 5:1984;77-82
23. Crimando J., Hoffman S.A. Detection of brain-reactive autoantibodies in the sera of autoimmune mice using ELISA. J. Immunol. Methods. 149:1992;87-95
24. Curzon G. The biochemistry of the basal ganglia and Parkinson's disease. Postgrad. Med. J. 53:1977;719-725
25. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 39:2003;889-909
26. David V., Durkin T.P., Cazala P. Rewarding effects elicited by the microinjection of either AMPA or NMDA glutamatergic antagonists into the ventral tegmental area revealed by an intracranial self-administration paradigm in mice. Eur. J. Neurosci. 10:1998;1394-1402
27. DeGiorgio L.A., Konstantinov K.N., Lee S.C., Hardin J.A., Volpe B.T., Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 7:2001;1189-1193
28. Denburg J.A., Carbotte R.M., Denburg S.D. Neuronal antibodies and cognitive function in systemic lupus erythematosus. Neurology. 37:1987;464-467
29. Denburg J.A., Carbotte R.M., Denburg S.D. Central nervous system lupus. Rheum. Rev. 2:1993;123-132
30. Denburg S.D., Behmann S.A., Carbotte R.M., Denburg J.A. Lymphocyte antigens in neuropsychiatric systemic lupus erythematosus. Relationship of lymphocyte antibody specificities to clinical disease. Arthritis Rheum. 37:1994;369-375
31. Denenberg V.H., Sherman G.F., Rosen G.D., Morrison L., Behan P.O., Galaburda A.M. A behavior profile of the MRL/Mp lpr/lpr mouse and its association with hydrocephalus. Brain Behav. Immun. 6:1992;40-49
32. Di Chiara G., Gessa G.L. Pharmacology and neurochemistry of apomorphine. Adv. Pharmacol. Chemother. 15:1978;87-160
33. Dixon F.J., Andrews B.S., Eisenberg R.A., McConahey P.J., Theofilopoulos A.N., Wilson C.B. Etiology and pathogenesis of a spontaneous lupus-like syndrome in mice. Arthritis Rheum. 21:1978;S64-S67
34. Donnan G.A., Woodhouse D.G., Kaczmarczyk S.J., Holder J.E., Paxinos G., Chilco P.J., Churchyard A.J., Kalnins R.M., Fabinyi G.C., Mendelsohn F.A. Evidence for plasticity of the dopaminergic system in parkinsonism. Mol. Neurobiol. 5:1991;421-433
35. Dziedzicka-Wasylewska M., Papp M. Effect of chronic mild stress and prolonged treatment with imipramine on the levels of endogenous Met-enkephalin in the rat dopaminergic mesolimbic system. Pol. J. Pharmacol. 48:1996;53-56
36. Farrell M., Sakic B., Szechtman H., Denburg J.A. Effect of cyclophosphamide on leucocytic infiltration in the brain of MRL/lpr mice. Lupus. 6:1997;268-274
37. Fast P.E., Hatfield C.A., Franz C.L., Adams E.G., Licht N.J., Merritt M.V. Effects of treatment with immunomodulatory drugs on thymus and spleen lymphocyte subpopulations and serum corticosterone levels. Immunopharmacology. 5:1982;135-155
38. Franklin K.B.J., Paxinos G. The Mouse Brain in Stereotaxic Coordinates. 1997;Academic Press, San Diego
39. Garcia-Moreno J.M., Chacon J. Juvenile parkinsonism as a manifestation of systemic lupus erythematosus: case report and review of the literature. Mov. Disord. 17:2002;1329-1335
40. Glenthoj B.Y. The brain dopaminergic system. Pharmacological, behavioural and electrophysiological studies. Dan. Med. Bull. 42:1995;1-21
41. Greenwood D.L., Gitlits V.M., Alderuccio F., Sentry J.W., Toh B.H. Autoantibodies in neuropsychiatric lupus. Autoimmunity. 35:2002;79-86
42. Grota L.J., Schachtman T.R., Moynihan J.A., Cohen N., Ader R. Voluntary consumption of cyclophosphamide by Mrl mice. Brain Behav. Immun. 3:1989;263-273
43. Grota L.J., Ader R., Moynihan J.A., Cohen N. Voluntary consumption of cyclophosphamide by nondeprived Mrl-lpr/lpr and Mrl+/+ mice. Pharm. Biochem. Behav. 37:1990;527-530
44. Hafler D.A., Weiner H.L. MS: a CNS and systemic autoimmune disease. Immunol. Today. 10:1989;104-107
45. Hanly J.G., Fisk J.D., Eastwood B. Brain reactive autoantibodies and cognitive impairment in systemic lupus erythematosus. Lupus. 3:1994;193-199
46. Harbeck R.J., Hoffman A.A., Hoffman S.A., Shucard D.W., Carr R.I. A naturally occurring antibody in New Zealand mice cytotoxic to dissociated cerebellar cells. Clin. Exp. Immunol. 31:1978;313-320
47. Hattori T. Conceptual history of the nigrostriatal dopamine system. Neurosci. Res. 16:1993;239-262
48. Hess D.C., Taormina M., Thompson J., Sethi K.D., Diamond B., Rao R., Feldman D.S. Cognitive and neurologic deficits in the MRL/lpr mouse: a clinicopathologic study. J. Rheumatol. 20:1993;610-617
49. Hoffman S.A., Harbeck R.J. CNS lupus and the blood-brain barrier. Neuwelt E.A. Implications of the Blood-Brain Barrier and Its Manipulation. 1989;469-494 Plenum, New York
50. Hoffman S.A., Madsen C.S. Brain specific autoantibodies in murine models of systemic lupus erythematosus. J. Neuroimmunol. 30:1990;229-237
51. Hoffman S.A., Hoffman A.A., Shucard D.W., Harbeck R.J. Antibodies to dissociated cerebellar cells in New Zealand mice as demonstrated by immunofluorescence. Brain Res. 142:1978;477-486
52. Hoffman S.A., Arbogast D.N., Day T.T., Shucard D.W., Harbeck R.J. Permeability of the blood cerebrospinal fluid barrier during acute immune complex disease. J. Immunol. 130:1983;1695-1698
53. Hoffman S.A., Arbogast D.N., Ford P.M., Shucard D.W., Harbeck R.J. Brain-reactive autoantibody levels in the sera of ageing autoimmune mice. Clin. Exp. Immunol. 70:1987;74-83
54. Hoffman S.A., Narendran A., Shucard D.W., Harbeck R.J. Autoantibodies, immune complexes, and behavioral disorders: neuropsychiatric involvement in systemic lupus erythematosus. Drug Dev. Res. 15:1988;237-251
55. Hopkins K.J., Wang G., Schmued L.C. Temporal progression of kainic acid induced neuronal and myelin degeneration in the rat forebrain. Brain Res. 864:2000;69-80
56. How A., Dent P.B., Liao S.K., Denburg J.A. Antineuronal antibodies in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 28:1985;789-795
57. Hu S.C., Chang F.W., Sung Y.J., Hsu W.M., Lee E.H. Neurotoxic effects of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in the substantia nigra and the locus coeruleus in BALB/c mice. J. Pharmacol. Exp. Ther. 259:1991;1379-1387
58. Jongen P.J., Boerbooms A.M., Lamers K.J., Raes B.C., Vierwinden G. Diffuse CNS involvement in systemic lupus erythematosus: intrathecal synthesis of the 4th component of complement. Neurology. 40:1990;1593-1596
59. Kier A.B. Clinical neurology and brain histopathology in NZB/NZW F1 lupus mice. J. Comp. Pathol. 102:1990;165-177
60. Koch F., Heufler C., Kampgen E., Schneeweiss D., Bock G., Schuler G. Tumor necrosis factor alpha maintains the viability of murine epidermal Langerhans cells in culture, but in contrast to granulocyte/macrophage colony-stimulating factor, without inducing their functional maturation. J. Exp. Med. 171:1990;159-171
61. Kumer S.C., Vrana K.E. Intricate regulation of tyrosine hydroxylase activity and gene expression. J. Neurochem. 67:1996;443-462
62. Kunas R.C., McRae A., Kesselring J., Villiger P.M. Antidopaminergic antibodies in a patient with a complex autoimmune disorder and rapidly progressing Parkinson's disease. J. Allergy Clin. Immunol. 96:1995;688-690
63. Kwong K.L., Chu R., Wong S.N. Parkinsonism as unusual neurological complication in childhood systemic lupus erythematosus. Lupus. 9:2000;474-477
64. Lai N.S., Lan J.L. Evaluation of cerebrospinal anticardiolipin antibodies in lupus patients with neuropsychiatric manifestations. Lupus. 9:2000;353-357
65. Lau Y.S., Fung Y.K. Pharmacological effects of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) on striatal dopamine receptor system. Brain Res. 369:1986;311-315
66. Lie D.C., Dziewczapolski G., Willhoite A.R., Kaspar B.K., Shults C.W., Gage F.H. The adult substantia nigra contains progenitor cells with neurogenic potential. J. Neurosci. 22:2002;6639-6649
67. Majovski L.V., Jacques S., Hartz G., Fogwell L.A. Dopaminergic (DA) systems: their role in pathological neurobehavioral symptoms. Neurosurgery. 9:1981;751-757
68. Maric D., Millward J.M., Ballok D.A., Szechtman H., Barker J.L., Denburg J.A., Sakic B. Neurotoxic properties of cerebrospinal fluid from behaviorally impaired autoimmune mice. Brain Res. 920:2001;183-193
69. McGuire S.O., Ling Z.D., Lipton J.W., Sortwell C.E., Collier T.J., Carvey P.M. Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp. Neurol. 169:2001;219-230
70. McHale J.F., Harari O.A., Marshall D., Haskard D.O. TNF-alpha and IL-1 sequentially induce endothelial ICAM-1 and VCAM-1 expression in MRL/lpr lupus-prone mice. J. Immunol. 163:1999;3993-4000
71. McNaught K.S., Olanow C.W. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann. Neurol. 53(Suppl. 3):2003;S73-S84
72. Mevorach D., Raz E., Steiner I. Evidence for intrathecal synthesis of autoantibodies in systemic lupus erythematosus with neurological involvement. Lupus. 3:1994;117-121
73. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165:1994;208-210
74. Monleon S., D'Aquila P., Parra A., Simon V.M., Brain P.F., Willner P. Attenuation of sucrose consumption in mice by chronic mild stress and its restoration by imipramine. Psychopharmacology (Berl.). 117:1995;453-457
75. Moore P.M. Autoantibodies to nervous system tissue in human and murine systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 823:1997;289-299
76. Morelli M., Fenu S., Garau L., Di Chiara G. Time and dose dependence of the 'priming' of the expression of dopamine receptor supersensitivity. Eur. J. Pharmacol. 162:1989;329-335
77. Murai T., Muller U., Werheid K., Sorger D., Reuter M., Becker T., von Cramon D.Y., Barthel H. In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 13:2001;222-228
78. Narendran A., Hoffman S.A. Identification of autoantibody reactive integral brain membrane antigens - A two dimensional analysis. J. Immunol. Methods. 114:1988;227-234
79. Osawa H., Yamabe H., Kaizuka M., Tamura N., Tsunoda S., Shirato K.I., Okumura K. Systemic lupus erythematosus associated with transverse myelitis and parkinsonian symptoms. Lupus. 6:1997;613-615
80. O'Sullivan F.X., Fassbender H.G., Gay S., Koopman W.J. Etiopathogenesis of the rheumatoid arthritis-like disease in MRL/l mice: I. The histomorphologic basis of joint destruction. Arthritis Rheum. 28:1985;529-536
81. Piani D., Spranger M., Frei K., Schaffner A., Fontana A. Macrophage-induced cytotoxicity of N-methyl-D-aspartate receptor positive neurons involves excitatory amino acids rather than reactive oxygen intermediates and cytokines. Eur. J. Immunol. 22:1992;2429-2436
82. Porsolt R.D. Animal model of depression. Biomedicine. 30:1979;139-140
83. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 229:1977;327-336
84. Probert L., Selmaj K. TNF and related molecules: trends in neuroscience and clinical applications. J. Neuroimmunol. 72:1997;113-117
85. Randall P.K. Lesion-induced DA supersensitivity in aging C57BL/6J mice. Brain Res. 308:1984;333-336
86. Rinne U.K., Rinne J.O., Rinne J.K., Laakso K., Laihinen A., Lonnberg P. Brain receptor changes in Parkinson's disease in relation to the disease process and treatment. J. Neural Transm., Suppl. 18:1983;279-286
87. Robak E., Sysajedrzejowska A., Robak T., Stepien H., Wozniacka A., Waszczykowska E. Tumour necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6) and their soluble receptors (sTNF-alpha-Rp55 and sIL-6R) serum levels in systemic lupus erythematodes. Mediat. Inflamm. 5:1996;435-441
88. Roth G.A., Monferran C.G., Maggio B., Cumar F.A. Central nervous system lipid alterations in rats with experimental allergic encephalomyelitis and its suppression by immunosuppressive drugs. Life Sci. 30:1982;859-866
89. Ryder E.F., Snyder E.Y., Cepko C.L. Establishment and characterization of multipotent neural cell lines using retrovirus vector-mediated oncogene transfer. J. Neurobiol. 21:1990;356-375
90. Sakic B., Szechtman H., Keffer M., Talangbayan H., Stead R., Denburg J.A. A behavioral profile of autoimmune lupus-prone MRL mice. Brain Behav. Immun. 6:1992;265-285
91. Sakic B., Szechtman H., Denburg S.D., Carbotte R.M., Denburg J.A. Brain-reactive antibodies and behavior of autoimmune MRL-lpr mice. Physiol. Behav. 54:1993;1025-1029
92. Sakic B., Szechtman H., Talangbayan H., Denburg S.D., Carbotte R.M., Denburg J.A. Disturbed emotionality in autoimmune MRL-lpr mice. Physiol. Behav. 56:1994;609-617
93. Sakic B., Szechtman H., Denburg S.D., Denburg J.A. Immunosuppressive treatment prevents behavioral deficit in autoimmune MRL-lpr mice. Physiol. Behav. 58:1995;797-802
94. Sakic B., Denburg J.A., Denburg S.D., Szechtman H. Blunted sensitivity to sucrose in autoimmune MRL-lpr mice: a curve-shift study. Brain Res. Bull. 41:1996;305-311
95. Sakic B., Szechtman H., Stead R., Denburg J.A. Joint pathology and behavioral performance in autoimmune MRL-lpr mice. Physiol. Behav. 60:1996;901-905
96. Sakic B., Szechtman H., Braciak T.A., Richards C.D., Gauldie J., Denburg J.A. Reduced preference for sucrose in autoimmune mice: a possible role of interleukin-6. Brain Res. Bull. 44:1997;155-165
97. Sakic B., Gurunlian L., Denburg S.D. Reduced aggressiveness and low testosterone levels in autoimmune MRL-lpr males. Physiol. Behav. 63:1998;305-309
98. Sakic B., Szechtman H., Denburg J.A., Gorny G., Kolb B., Whishaw I.Q. Progressive atrophy of pyramidal neuron dendrites in autoimmune MRL-lpr mice. J. Neuroimmunol. 87:1998;162-170
99. Sakic B., Kolb B., Whishaw I.Q., Gorny G., Szechtman H., Denburg J.A. Immunosuppression prevents neuronal atrophy in lupus-prone mice: evidence for brain damage induced by autoimmune disease? J. Neuroimmunol. 111:2000;93-101
100. Sakic B., Maric I., Koeberle P.D., Millward J.M., Szechtman H., Maric D., Denburg J.A. Increased TUNEL-staining in brains of autoimmune Fas-deficient mice. J. Neuroimmunol. 104:2000;147-154
101. Sakic B., Lacosta S., Denburg J., Szechtman H. Altered neurotransmission in brains of autoimmune mice: pharmacological and neurochemical evidence. J. Neuroimmunol. 129:2002;84-96
102. Schmued L.C., Hopkins K.J. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res. 874:2000;123-130
103. Schultz S.K., Ellingrod V., Fleming F.W., Andreasen N.C. The association between risk factors for tardive dyskinesia and phenylalanine-induced abnormal movements in schizophrenia. Hum. Psychopharmacol. 16:2001;273-277
104. Seabrook T.J., Hay J.B. Intracerebroventricular infusions of TNF-alpha preferentially recruit blood lymphocytes and induce a perivascular leukocyte infiltrate. J. Neuroimmunol. 113:2001;81-88
105. Shahani N., Gourie-Devi M., Nalini A., Raju T.R. Cyclophosphamide attenuates the degenerative changes induced by CSF from patients with amyotrophic lateral sclerosis in the neonatal rat spinal cord. J. Neurol. Sci. 185:2001;109-118
106. Sherman G.F., Morrison L., Rosen G.D., Behan P.O., Galaburda A.M. Brain abnormalities in immune defective mice. Brain Res. 532:1990;25-33
107. Shiraki M., Fujiwara M., Tomura S. Long term administration of cyclophosphamide in MRL/1 mice: I. The effects on the development of immunological abnormalities and lupus nephritis. Clin. Exp. Immunol. 55:1984;333-339
108. Sibbitt W.L. Jr., Sibbitt R.R. Magnetic resonance spectroscopy and positron emission tomography scanning in neuropsychiatric systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 19:1993;851-868
109. Snippe H., Davidse R.P., Belder M., Willers J.M. Effects of cyclophosphamide treatment on the in vitro activity of mouse lymphoid cells after nonspecific and specific stimulation. Int. Arch. Allergy Appl. Immunol. 50:1976;536-547
110. Snyder E.Y., Deitcher D.L., Walsh C., Arnold-Aldea S., Hartwieg E.A., Cepko C.L. Multipotent neural cell lines can engraft and participate in development of mouse cerebellum. Cell. 68:1992;33-51
111. Sriram K., Matheson J.M., Benkovic S.A., Miller D.B., Luster M.I., O'Callaghan J.P. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J. 16:2002;1474-1476
112. Starr B.S., Starr M.S. Behavioural interactions involving D1 and D2 dopamine receptors in non-habituated mice. Neuropharmacology. 26:1987;613-619
113. Svenungsson E., Andersson M., Brundin L., van Vollenhoven R., Khademi M., Tarkowski A., Greitz D., Dahlstrom M., Lundberg I., Klareskog L., Olsson T. Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann. Rheum. Dis. 60:2001;372-379
114. Szechtman H., Sakic B., Denburg J.A. Behaviour of MRL mice: an animal model of disturbed behaviour in systemic autoimmune disease. Lupus. 6:1997;223-229
115. Tan E.K., Chan L.L., Auchus A.P. Reversible parkinsonism in systemic lupus erythematosus. J. Neurol. Sci. 193:2001;53-57
116. Tanaka A., O'Sullivan F.X., Koopman W.J., Gay S. Etiopathogenesis of rheumatoid arthritis-like disease in MRL/1 mice: II. Ultrastructural basis of joint destruction. J. Rheumatol. 15:1988;10-16
117. ten Berge R.J., van Walbeek H.K., Schellekens P.T. Evaluation of the immunosuppressive effects of cyclophosphamide in patients with multiple sclerosis. Clin. Exp. Immunol. 50:1982;495-502
118. Theofilopoulos A.N. Murine models of lupus. Lahita R.G. Systemic Lupus Erythematosus. 1992;121-194 Churchill Livingstone, New York
119. Thiebot M.H., Martin P., Puech A.J. Animal behavioural studies in the evaluation of antidepressant drugs. Br. J. Psychiatr., Suppl. 1992;44-50
120. Thiruchelvam M., McCormack A., Richfield E.K., Baggs R.B., Tank A.W., Di Monte D.A., Cory-Slechta D.A. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur. J. Neurosci. 18:2003;589-600
121. Tillerson J.L., Cohen A.D., Philhower J., Miller G.W., Zigmond M.J., Schallert T. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J. Neurosci. 21:2001;4427-4435
122. Trekova N.A., Vetrile L.A., Basharova L.A., Mikovskaya O.I., Khlopushina T.G. Anti-dopamine antibodies: effects on behavior in an "open field, " pain sensitivity, CNS monoamine content, and functional activity of immunocytes in C57Bl/6 mice. Neurosci. Behav. Physiol. 31:2001;7-13
123. Vogelweid C.M., Johnson G.C., Besch-Williford C.L., Basler J., Walker S.E. Inflammatory central nervous system disease in lupus-prone MRL/lpr mice: comparative histologic and immunohistochemical findings. J. Neuroimmunol. 35:1991;89-99
124. Wagner J., Akerud P., Castro D.S., Holm P.C., Canals J.M., Snyder E.Y., Perlmann T., Arenas E. Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes. Nat. Biotechnol. 17:1999;653-659
125. Watanabe-Fukunaga R., Brannan C.I., Copeland N.G., Jenkins N.A., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 356:1992;314-317
126. Watanabe-Fukunaga R., Brannan C.I., Itoh N., Yonehara S., Copeland N.G., Jenkins N.A., Nagata S. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol. 148:1992;1274-1279
127. Wekking E.M. Psychiatric symptoms in systemic lupus erythematosus - an update. Psychosom. Med. 55:1993;219-228
128. Williams G.W., Bluestein H.G., Steinberg A.D. Brain-reactive lymphocytotoxic antibody in the cerebrospinal fluid of patients with systemic lupus erythematosus: correlation with central nervous system involvement. Clin. Immunol. Immunopathol. 18:1981;126-132
129. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int. Clin. Psychopharmacol. 12(Suppl. 3):1997;S7-S14
130. Winkler J.D., Callison K., Cass S.A., Weiss B. Selective down-regulation of D1 dopamine mediated rotational behavior in supersensitive mice. Neuropharmacology. 27:1988;439-442
131. Wolters E.C. Intrinsic and extrinsic psychosis in Parkinson's disease. J. Neurol. 248(Suppl. 3):2001;III22-III27
132. Yang M., Stull N.D., Berk M.A., Snyder E.Y., Iacovitti L. Neural stem cells spontaneously express dopaminergic traits after transplantation into the intact or 6-hydroxydopamine-lesioned rat. Exp. Neurol. 177:2002;50-60
133. Ye X., Carp R.I., Schmued L.C., Scallet A.C. Fluoro-Jade and silver methods: application to the neuropathology of scrapie, a transmissible spongiform encephalopathy. Brain Res. Brain Res. Protoc. 8:2001;104-112
134. Zameer A., Hoffman S.A. Immunoglobulin binding to brain in autoimmune mice. J. Neuroimmunol. 120:2001;10-18
135. Zameer A., Hoffman S.A. B and T cells in the brains of autoimmune mice. J. Neuroimmunol. 146:2004;133-139
136. Ziegler, M., Szechtman, H., 1988. Differences in the behavioral profile of circling under amphetamine and apomorphine in rats with unilateral lesions of the substantia nigra. Behav. Neurosci. 102, 276-88, 327.